Tandem Diabetes Care, Inc. Launches $15,000,000 “At-the-Market” Offering

Tandem Diabetes Care, Inc.

Represented Tandem Diabetes Care, Inc. (NSDQ:TNDM) in an Equity Distribution Agreement with Piper Jaffray & Co., pursuant to which it may offer and sell up to an aggregate of $15,000,000 of shares of its common stock through Piper, as its agent, pursuant to a shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (SEC) on December 19, 2014, and a prospectus supplement that was filed with the SEC on July 27, 2017. Tandem intends to use the proceeds from the offering for working capital and other general corporate purposes.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.

The Newport Beach-based team representing Tandem included Bruce Feuchter, Ryan WilkinsJason Lee and Sonya Attal.